Clients say that he is a “pharmaceuticals sector expert.”

The Legal 500 2018

Robbie McLaren

London
  • 99 Bishopsgate
  • London EC2M 3XF
  • United Kingdom
 
 

Robbie McLaren is a partner in the London office of Latham & Watkins and Co-Chair of the London Corporate Department. His practice focuses primarily on cross-border M&A, joint ventures, venture capital, reorganizations, and general corporate matters. Mr. McLaren has represented clients who operate in a number of industries, with a particular focus on clients in the life sciences, healthcare, and technology industries.

 

Mr. McLaren's representative experience includes advising:
Life Sciences and Healthcare
  • BC Partners on the acquisition of a majority interest in the complex generic medicines business of Synthon International, a Dutch based multinational pharmaceutical company
  • Atnahs Pharma on its acquisition of assets related to five hypertension medicine brands from AstraZeneca
  • Acino on its acquisition of various pharmaceutical products and related assets in the NEMEA region from Takeda
  • Apotex on the sale of two pharmaceutical products to Intas which are aimed at stimulating white blood cells during chemotherapy
  • Abcam plc in regards to its license and asset purchase agreement with Roche Tissue Diagnostics to obtain exclusive rights to the product portfolio of Spring Bioscience Corporation (Spring)
  • 8VC on the sale of their shares in Digital Surgery to Medtronic
  • Baxter International Inc., in connection with its US$625 million acquisition of Claris Injectables Limited, an India-based manufacturer of sterile injectables
  • Sienna Biopharmaceuticals in connection with its acquisition of Creabilis plc, a privately held specialty pharmaceutical company
  • An Asian investor on their investment into Aerogen, an acute aerosol drug delivery business   
  • The shareholders of Pharmathen SA, a Greek pharmaceuticals company, on their sale of a controlling interest in Pharmathen to BC Partners
  • Zogenix on its acquisition of Brabant Pharma, a UK-based pharmaceutical company
  • Novo A/S on its:
    • £230 million disposal of Archimedes and its US$706 million acquisition of Xellia
    •  Investments Entasis Therapeutics and Adaptimmune
  • Watson Pharmaceuticals / Actavis / Allergan on its:
    • €4.25 billion acquisition of the Actavis Group, making Watson the third largest global generics company
    • Divestment of part of its Western European generics sale and marketing business to Aurobindo
    • US$40.5 billion sale of its global generics pharmaceuticals business to Teva
  • Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with its
    • US$703 million acquisition by CVC Capital Partners of women’s healthcare assets from Teva Pharmaceutical Industries Ltd
    • Acquisition of certain pharmaceutical products from Janssen
Technology, Media, and Telecoms
  • Mimecast on the acquisition of Simply Migrate, a London-based provider of archive data migration technology
  • Sony Pictures Entertainment and its subsidiary, Columbia Pictures Corporation, on the acquisition of Silvergate Media, a developer of children’s brands for broadcasters, streaming platforms, and retail partners (including the Octonauts, Peter Rabbit, and Hilda animated series)
  • Selina on their equity financings, including its US$125m Series C financing 
  • Hyundai on its investment into AppyParking, a company providing parking apps and services for drivers
  • An Asian investor on their equity investment in:
    • Sound Cloud, a Germany-based company engaged in providing online audio platform services
    • Claroty, a cybersecurity software company
    • Common Sense Robotics
  • Telenor on its €2.8 billion sale of its assets in Central and Eastern Europe (CEE) to PPF Group
  • Kite Tech, a UK-based mobile e-commerce platform specializing in personalized print on its sale to Canon Europa
  • Netflix Inc. on the acquisition of Millarworld, a comic book company founded by Mark Millar
  • Andreessen Horowitz on its minority investment in Improbable World Limited, a UK-based software developer focused on virtual and simulated worlds
  • Intapp on their acquisition of Rekoop
  • The Carlyle Group on its US$400 million investment in Ion Trading and its US$700 million acquisition of Dealogic
  • Calysta on their acquisition of BioProtein A/S    
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.